David Henry

Associate Professor Emeritus
Primary office:
School of Pharmacy
Room 2001H / KU Medical Center, MS 4047 B440 Bell


Department of Pharmacy Practice Chair David Henry received his BS in pharmacy and MS in hospital pharmacy administration from KU. He became interim chair of the Department of Pharmacy Practice in November, 2010, and chair in May, 2011.

He was named a fellow in the American Society of Health-System Pharmacists in 1993 and became a board-certified oncology pharmacist in 1998. His clinical specialty since 1986 has been pediatric hematology/oncology, working with the KU Hospital PHO team.

Henry has been very active in the Pediatric Oncology Group (1991) and subsequently the Children’s Oncology Group (2000) for more than 20 years, and much of his scholarly activity has been through this association. He has also been active in ASHP, AACP, and HOPA.

Courses and Rotations

  • PHPR 502 (OTC’s)
  • PHPR 646 (Oncology Therapeutics)
  • PHPR 508 (Oncology Pharmacy Elective, Coordinator)

Additional lectures in:

  • PHCH (Clinical Pharmacokinetics)
  • PHCH 667 (Intro to Clinical Laboratory)


  • Pediatric Hematology/Oncology

Professional Leadership and Service

  • Nominations and Awards Committee, Hematology and Oncology Pharmacists Association, 2011, 2012 (Vice-chair)
  • Kappa Psi, Rho chapter, University of Kansas School of Pharmacy, Grand Council Deputy (Advisor, 2001- present)
  • Student Society of Health-System Pharmacists Advisor, 2007-present 
  • ASHP “Student Forum” faculty liaison to the University of Kansas School of Pharmacy, 1986-2001, 2007–present
  • Liaison to Kansas Council of Health-System Pharmacists, 2010–present
  • Specialty Council on Oncology Pharmacy, Board of Pharmaceutical Specialties, 2006–2011. Chair, 2010 and 2011
  • Pharmacy Committee Core Committee, Children’s Oncology Group, 2001-2010
  • Core committee of the Nutrition subcommittee of Cancer Control, Children’s Oncology Group, 2005-2010
  • Group Chair’s Protocol Review Committee, Children’s Oncology Group, 2005-2008    


  • Pharmacotherapy in cancer and supportive care of oncology patients
  • Children’s Oncology Group: Soft tissue and bone sarcomas; Nutrition support; Obesity and chemotherapy
  • Drug combinations in intraperitoneal therapy for colorectal carcinomatosis (preclinical)

Recent Awards and Honors

  • Kansas Council of Health-System Pharmacists Legacy Award, 2012
  • Harold N. Godwin Leadership Legacy Award, 2009
  • Preceptor of the Year, KU School of Pharmacy, 2001-2, 2002-3, 2006-7, 2011-12 (selected by graduating students)

Selected Publications

  • Skapek SX, Anderson JR, Hill DA, Henry D., et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 2012;   DOI 10.1002/pbc.24457
  • Felgenhauer JL, Nieder ML, Grailo MD, Bernstein ML, Henry D.W., et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic ewing sarcoma family of tumors: A Children’s Oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer 2012; Oct 12. doi:10.1002/pbc.24328 (Epub ahead of print)
  • Henry D.W., Holdsworth MT, Kaiser NA. Pediatric Malignancies. In Koda-Kimble MA, Young LY, Alldredge BK, et al. Applied Therapeutics: The Clinical Use of Drugs. Lippincott, Williams & Wilkins. Philadelphia. 10th edition. 2012. pp. 2143-2171
  • Lee A, Henry D.W., Ng JS, Parsons K, Poon BB, Schwartz J, Smith T, Assanasen C. Ifosfamide neurotoxicity in pediatric patients: a multi-institutional case series report, J Hematol Oncol Pharm 2011;1:12-17
  • Kettle JK, Grauer D, Folker TL, O’Neal N, Henry D.W., Williams CB. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy,  Pharmacotherapy 2010;30:812-17 (Won HOPA Literature Award in 2011 for Dr. Kettle)
  • Cohen MS, Al-kasspooles MF, Williamson SK, Henry D., Broward M, Roby KF. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo, Ann Surg Oncol 2010;17(1):296.  (DOI 10.1245/s10434-009-0669-0, Online 26 Aug 2009)

Selected Presentations

  • “Pharmacists and the Healthcare Team” Community Health Program (interprofessional student summer experience and research program, University of Kansas Medical Center) June 27, 2012
  • “Pediatric Ewing Sarcoma: Dose-Dense Therapy” 7th Annual HOPA meeting, Salt Lake City, UT, March 23, 2011
  • “Chemotherapy-induced Nausea and Vomiting: Antiemetic Agents” Cancer Center Staff at Stormont Vail Hospital, Topeka, KS, May 25, 2010
  •  “Issues in Dosing Chemotherapy” Hematology Oncology Pharmacy Association, 5th Annual Meeting, June, 2009, Miami, FL
  • “Emerging toxicities in Pediatric Oncology” Hematology Oncology Pharmacy Association, 3rd Annual Meeting, June 16, 2007, Denver, CO

2nd among all schools of pharmacy in National Institutes of Health funding
Brings more than $20 million in external funding into the state each year
7 of 19 cancer drugs formulated through the National Cancer Institute were developed at the KU School of Pharmacy
3,000 free flu shots given to Kansans in need during the past 5 years
4,000 living alumni, 63 percent of them living and working in Kansas
KU pharmacists practice in 95 of Kansas’ 105 counties
20th among public schools of pharmacy.
—U.S. News & World Report
$20.2 million NIH research grant earned by Distinguished Professor Jeff Aubé was 2nd largest in Kansas history
100 percent placement after graduation for KU Pharm.D. students
Established in 1885 as the 1st professional program at KU
KU Today